首页> Cancer Chemotherapy and Pharmacology> Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: An NSABP Foundation Research Program phase i study

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: An NSABP Foundation Research Program phase i study

导出原文传递

翻译打印收藏纠错

第一作者： Jankowitz,R.C.

作者： Jankowitz,R.C. ^[1] ; Abraham,J. ; Tan,A.R. ; Limentani,S.A. ; Tierno,M.B. ; Adamson,L.M. ; Buyse,M. ; Wolmark,N. ; Jacobs,S.A.

作者单位： National Surgical Adjuvant Breast and Bowel Project (NSABP), East Commons Professional Building, 4 ^[1]

关键词 Breast cancer HER2 Neratinib Paclitaxel Phase I Trastuzumab

发布时间 2014-04-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer Chemotherapy and Pharmacology

2013年72卷6期

1205-1212页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer Chemotherapy and Pharmacology

2013年72卷6期

1205-1212页

检索历史清除

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: An NSABP Foundation Research Program phase i study

Cancer Chemotherapy and Pharmacology

相似文献

同项目论文

Cancer Chemotherapy and Pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: An NSABP Foundation Research Program phase i study

Cancer Chemotherapy and Pharmacology

相似文献

同项目论文

Cancer Chemotherapy and Pharmacology

相关期刊

检索历史清除